Global surgical robotics company CMR Surgical in Cambridge has closed a funding round of more than $200 million to underpin worldwide expansion – notably in the US.
The haul has been raised through a combination of equity and debt capital to support the company’s ambitious growth plans.
The fundraising, which was supported by all the company’s existing major investors, includes a new debt investment from Phoenix, Arizona-based Trinity Capital, reflecting strong investor confidence in CMR’s vision.
CMR will use the funds to accelerate commercial expansion of the Versius Surgical Robotic System to more hospitals around the world – with a major focus on launching Versius in the United States – and to continue advancing surgical robotics innovation and product development, including the launch of the newly enhanced Versius Plus.
Versius, the second most utilised soft tissue surgical robot in the world, has been used to complete more than 30,000 surgical cases globally in more than 30 different countries across a wide range of specialities including colorectal, general, gynaecology, thoracic and urology surgeries.
The increase in Versius installations has been fuelled by increasing adoption of surgical robotics and is a testament to the versatility of CMR’s system and its strong market differentiation.
CMR is also actively expanding its clinical footprint with two ongoing clinical trials: a pioneering paediatrics study, which is the world’s first multicentre prospective trial on the use of Versius in paediatric surgery, and a transoral robotic surgery (TORS) trial, further demonstrating the versatility and capability of Versius in new surgical applications.
Date: 9 April